Appointed
Richard van den Broek
Director
CRVS ·
Corvus Pharmaceuticals, Inc.
appointed Richard van den Broek to the Board.
Ready 8-Ks
25
Latest filing
May 14, 2026, 7:01 AM ET
Top materiality
0.80
Event mix
other_material ×12 · earnings ×9 · leadership ×3
Sentiment
11 pos · 0 neg · 14 neu
Latest earnings
▼ miss 2026-Q1
Executive change
recent →
Recent 8-K filings for CRVS
Highest-materiality recent filing
Corvus Pharmaceuticals prices $22.15/share public offering of ~9.1M shares for ~$188.3M net proceeds
- Upsized public offering of 7,900,677 shares at $22.15/share; underwriters fully exercised 30-day option for 1,185,101 additional shares.
- Expected net proceeds of approximately $188.3 million after underwriting discounts and expenses.
-
72-patient Phase 1 trial met safety and efficacy endpoints; no severe adverse events.
-
Corvus reports Q1 2026 net loss of $13.7M; cash $236.7M; soquelitinib trials advance
Net loss $13.7M in Q1 2026 vs net income $15.2M in Q1 2025; cash $236.7M (incl. $189.4M from Jan 2026 financing).
-
Corvus ups at-the-market equity facility to $200M from $100M
Amended Sales Agreement with Jefferies allows up to $200M in common stock sales, increased from $100M.
-
Corvus Q4 net loss $12.3M; soquelitinib atopic dermatitis Ph1 75% EASI75; raises $189M
Net loss for Q4 2025 was $12.3M; R&D expenses $9.9M (up from $6.0M in Q4 2024).
-
Corvus Pharmaceuticals prices $22.15/share public offering of ~9.1M shares for ~$188.3M net proceeds
Upsized public offering of 7,900,677 shares at $22.15/share; underwriters fully exercised 30-day option for 1,185,101 additional shares.
-
Corvus reports positive Phase 1 soquelitinib data in atopic dermatitis; Phase 2 planned Q1 2026
Cohort 4: 75% of soquelitinib patients achieved EASI 75 vs 20% placebo; 25% achieved EASI 90 vs 0% placebo.
-
Corvus Pharms Q3 net loss $10.2M, cash $65.7M; soquelitinib trials advancing
Net loss of $10.2M for Q3 2025, improved from $40.2M loss in Q3 2024 which included $32.8M non-cash warrant liability loss.
-
Corvus Q2 net loss $8M, cash $74.4M; soquelitinib atopic dermatitis data shows deeper EASI reduction
Net loss $8.0M for Q2 2025 vs $4.3M Q2 2024; R&D expenses $7.9M (up from $4.1M).
-
Soquelitinib met primary endpoint with statistically significant EASI improvement vs placebo at day 28 (p=0.036).
-
Corvus Q1 net income $15.2M; soquelitinib atopic derm cohort 3 EASI −71.1% vs placebo −42.1%
Net income of $15.2M included $25.1M gain on warrant liability; R&D spend $7.5M vs $4.1M YoY.
-
Net loss for Q4 2024 was $12.1M vs $6.7M in Q4 2023; full-year R&D expense $19.4M.
-
Corvus reports soquelitinib Phase 1 atopic dermatitis data: 26% IGA 0/1, 37% EASI 75 vs 0% placebo
19 soquelitinib patients: 26% achieved IGA 0/1, 37% achieved EASI 75 at day 28.
-
Soquelitinib 100mg BID: mean EASI reduction 55.9% at Day 28 vs 27% placebo; 69.1% at Day 58 vs 19.1% placebo.
-
Corvus Q3 net loss $40.2M; soquelitinib atopic dermatitis interim data due Dec 2024
Net loss of $40.2M for Q3 2024, including $32.8M non-cash warrant liability loss, vs $6.0M loss in Q3 2023.
-
Corvus reports Q2 loss; soquelitinib shows early activity in atopic derm, PTCL Phase 3 on track
Early soquelitinib Phase 1 atopic dermatitis data (3 evaluable patients, 100 mg BID) show clinical activity and cytokine changes consistent with ITK inhibition.
-
Corvus Q1 net loss $5.7M; soquelitinib PTCL ORR 39%; $30.6M financing
Net loss $5.7M in Q1 2024 vs $7.9M in Q1 2023; R&D expense $4.1M.
-
Corvus Pharmaceuticals raises $30.2M in registered direct offering with CEO participation
Entered Securities Purchase Agreement on May 1, 2024 to issue ~13.5M shares and warrants at $1.7312 per combined unit
-
Corvus cuts ATM program ceiling from $90M to $8.2M; nearly all capacity used
Amendment reduces aggregate offering price under Jefferies ATM from $90M to $8.2M.
Executive changes
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.65 · Most common event other_material